BGB Group’s Post

Today I wanted to share this article that I read from the Cochrane Library, published 2 months ago. Platinum‐based chemotherapy for early triple‐negative breast cancer Summarized Information: Background: - Triple negative breast cancer (TNBC) makes up ~ 15% of all breast cancers. It affects African American and Hispanic woman at higher rates with worse outcomes. 5 year survival rates are as follows: 91% (localized), 66% (regional), 12% (distant), and 77% (all stages combined). [Reference: Breast Cancer Research Foundation and the American Cancer Society] Objective: - Systemic Review to evaluate platinum‐based adjuvant and neoadjuvant chemotherapy (carboplatin) benefit and risks in patients with early TNBC. Methods: - Standard Cochrane methods, only randomized controlled trials, included 20 published studies involving 21 treatment comparisons and 25 ongoing studies. Primary Outcome: - Disease‐free survival (DFS) and overall survival (OS). Results: - Survival outcome follow-up ranged from 36-97.6 months. - Disease Free Survival --> hazard ratio 0.63, 95% confidence interval 0.53 to 0.75 - Overal Survival --> hazard ratio 0.69, 95% confidence interval 0.55 to 0.86. Conclusion: - Platinum‐based adjuvant and neoadjuvant chemotherapy (carboplatin) has been shown to improve both DFS and OS. However, there were increased chemotherapy delays and dose reductions. Further research is needed to determine the optimal dose and regimen. https://lnkd.in/e5-us653 #pharma #biotech #medicalaffairs #msl #medicine #oncology

🎙 Recently I spoke with Navid Alipour, the founder and CEO of CureMetrix and CureMatch, Inc.🎙 🤖 We delved into the fascinating world of using AI to power early detection and provide better treatments in oncology and cardiology. Here are three key takeaways from our insightful conversation with Navid: ⭐ Early Detection is Key: Navid shared how Curemetrix is revolutionizing breast cancer detection using AI technology. With their FDA-cleared products, they can detect breast cancer and even early signs of heart disease from mammograms. This early detection can potentially save lives by enabling timely interventions and treatments. ⭐ Personalized Precision Medicine: Through Curematch, Navid and his team are pioneering personalized precision medicine in oncology. By analyzing the molecular makeup of a patient's cancer through next-gen sequencing, Curematch provides oncologists with tailored treatment recommendations. This approach not only improves patient outcomes but also helps pharma companies bring cancer drugs to market faster. ⭐ The Power of AI and Collaboration: Navid emphasized the importance of partnerships and collaborations in expanding the reach and impact of their AI-driven solutions. By working with larger pharmaceutical companies and healthcare providers, Curemetrix and Curematch aim to make a significant difference in improving women's health and advancing cancer care globally. If you want to learn more about the groundbreaking work being done by Navid Alipour and his teams you can listen to the full episode at the link below. https://lnkd.in/d_Nxj7TW 💥 #AIinHealthcare #AIinoncology #EarlyDetection #HealthTechInnovation

The goal of precision medicine is simply to deliver the right cancer treatment to the right patient at the right dose and at the right time. Molecular profiling of tumors is used to identify targetable alterations, which is rapidly developing and has entered the mainstream of clinical practice. The two types of treatment most often used in precision medicine are targeted drug therapy (drugs designed to attack a specific target on cancer cells) and immunotherapy (medicines used to help the body's immune system attack the cancer). Molecular testing enables the classification and diagnosis of cancers with greater precision, potentially improving prognosis, therapeutic decision-making, and outcomes, while sparing patients from treatments that may confer less clinical benefit. The VieCure platform supports precision medicine through our patented A.I. inference engine, which auto-populates the best treatment possible by taking specific patient data and real-time clinical guidelines to ensure that the patient is receiving the most up-to-date, precise treatment option. The clinical brain also assists physicians with the ease of molecular diagnostics ordering by sending out a consideration that lets the care team know what test should be ordered and when it should be ordered, all while staying in clinical workflow with VieCure’s one-click ordering capability. The VieCure platform is the ultimate tool to assist physician decision-making while also improving the delivery of precision oncology to each patient, every time. #VieCure #precisionmedicine #precisiononcology

#Patient success is the most powerful driver behind development of new #therapies. Making this personal is the right step towards more successes! #oncology #analytics #drugdevelopment #clinicaltrials

To dosimetrists and those in the RPT space. What do you think about the source post and the comments below? Will the importance of Dosimetry continue to grow? How ready is your hospital or clinic? #dosimetry #radiopharmaceuticals #cancerresearch

ℹ️ Exciting news in medical research! Real-world data (RWD) will soon be collected on patients with non-small cell lung cancer receiving osimertinib, with or without chemotherapy, in routine clinical practice. This innovative study aims to enhance our understanding of the safety and effectiveness of osimertinib, a newly approved therapy that physicians routinely prescribe. The data collected by PrECOG Cancer Research Group and ECOG-ACRIN Cancer Research Group in this registry will have the potential to provide valuable insights into side effects, patient benefits, survival rates, patient-reported outcomes, and outcomes based on various demographic variables. Stay tuned for updates on this groundbreaking research! 🌟🔬 #MedicalResearch #Osimertinib #FDA https://lnkd.in/e8vuP63w

Ga-68 FAPI-PET/CT Predicts #Chemotherapy Responses Revolutionizing #Breast #Cancer Care A groundbreaking #study published in the Journal of #nuclearmedicine, #researchers uncovered a potential game-changer in breast cancer #treatment. The focus is on Ga-68 FAPI-PET/CT scans, showcasing their ability to predict responses to neoadjuvant chemotherapy (NAC) in breast cancer patients. Ga-68 FAPI-PET/CT parameters can offer rapid feedback on #tumor changes after just two cycles of #chemotherapy, providing crucial early insights. Ga-68 FAPI stands out for its specificity in predicting complete responses compared to the commonly used F-18 FDG-PET/CT. The study's findings prompt a call to action for further #research, considering cancer subtypes and chemotherapy regimens. Ga-68 FAPI-PET/CT holds potential not only as a #diagnostic tool but as a critical early response indicator, paving the way for more personalized and effective breast cancer treatments. #nuclearmedicine #pet #petct #radiology #biotech #drugdevelopment Read the Full Article: https://lnkd.in/gpBkZQEV Reach our team at: [email protected]   About Image Analysis Group (IAG) IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development, bringing R&D solutions, operational breadth, and radiological expertise via risk-sharing financing and partnering models.

Some interesting insight in Phesi Global Data Analysis (https://lnkd.in/gByuSZ8m) regarding the leading disease areas in terms of clinical development around the world. I would like to share with you my top takeaways: • Breast cancer and solid tumors are the most studied diseases for the third consecutive year. • Stroke has become the third most studied disease area, up from fifth place in 2022. • Covid-19 has dropped from second to fourth position, while prostate cancer has dropped from third to fifth most studied disease in 2023. • Both prostate cancer and stroke entered the top five most studied disease areas in 2022, replacing non-small cell lung cancer and multiple myeloma from Phesi’s 2021 global analysis. • Trial recruitment across all five top indications in 2023 has been positive, with an increase in solid tumor trials. • An increased attrition rate at Phase II has been observed, with nearly a third (28%) of clinical trials cancelled during Phase II. • Phase III cancellations are expected to rise in the coming years, with trials that struggled to meet scientific and medical objectives during Phase II less likely to reach the end of Phase III successfully. • The US is home to 33% of the 115,000 recruiting investigator sites from interventional trials around the world, but its importance has been declining from 45% in the past 15 years. • The war in Ukraine has significantly impacted global recruiting investigator sites in clinical development. • The long-term impact of the pandemic on the clinical development industry looks set to stretch into 2025 before Phase II trials return to their pre-Covid-19 attrition rate. • To minimize the impact of disruption across trials, there is a growing need for trial design and execution to become more data-led. #clinicaltrial #newdrugdevelopment #clinicaldevelopment #pharmaportfolio #researchanddevelopment

Groundbreaking #Oncology Trial Results Published on January 23rd, 2024 🎉 We are thrilled to share the publication of three Phase 2 clinical trial results in the fight against cancer, covering advanced breast cancer, metastatic urothelial cancer, and advanced soft tissue sarcoma. These studies highlight innovative treatments and promising outcomes for patients facing these challenging conditions. 1. 🎗️ Breast Cancer Breakthroughs: In a Phase 2 study of poziotinib for HER2-positive advanced breast cancer, patients who had previously undergone anti-HER2 regimens showed an objective response rate (ORR) of 30%. Despite facing adverse events like diarrhea and rash, a median progression-free survival (PFS) of up to 4.9 months was reported. #BreastCancerAwareness #HER2Positive 2. 💪 Fighting Metastatic Urothelial Cancer: The combination of sacituzumab govitecan and pembrolizumab has shown an impressive objective response rate of 41% in a Phase 2 trial for metastatic urothelial cancer, with a clinical benefit rate of 46% and a median duration of response of 11.1 months. This beacon of hope for patients signifies a remarkable advancement in treatment. #UrothelialCancerFight #CancerResearch 3. 🏋️♂️ Progress in Soft Tissue Sarcoma: A single-arm Phase 2 trial investigating pazopanib combined with durvalumab in metastatic or recurrent soft tissue sarcoma reported an overall response rate of 30.4% and a median progression-free survival of 7.7 months. This study marks a significant step forward in treating this challenging condition. #SarcomaResearch #InnovativeTreatments For more detailed information on these groundbreaking studies, follow this link https://lnkd.in/dsZBeCP3. Let's keep the conversation going! Like, share, and follow for more updates on how we're making strides in cancer treatment together. Your support can help spread hope and awareness to those in need. #CancerCare #ClinicalTrials #MedicalInnovation

What was the best part of the oral prostate cancer session at #ASCO24 yesterday? When an audience member asked why a control arm inferior to the standard of care was used in the randomized clinical trial being discussed. Let me explain: ARPI = abiraterone, enzalutamide, darolutamide, apalutamide. We know in metastatic castrate resistant prostate cancer (mCRPC) that use of an ARPI after a prior ARPI has failed basically doesn’t work.  However, we do have other life prolonging options in this setting that are routinely used in clinical practice. New randomized phase 3 trials for patients with mCRPC who have failed a prior ARPI continue to be designed that compare fancy new drug regimen X to…..an ARPI.  This is effectively a placebo. Using inferior control arms to compare new regimen X against an ineffective therapy increases the chance new regimen X wins….and harms patients. There is a simple solution:  Don’t restrict the control arm to an ARPI in this setting.  Allow the treating physician to choose among all available life prolonging therapies.  Vinay Prasad talks about this important issue all the time.  If you’re unfamiliar with the concept, study his work. Back to the audience member yesterday….bravo to that person!  I am glad to see that researchers from leading medical centers are increasingly addressing this issue out loud and in public. Patients, KOLs, clinical trialists, advocacy groups, government agencies: demand better randomized clinical trial designs!